Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Biodistribution Study of 153Sm-EDTMP Produced by Irradion of Natural and Enriched Samarium, in Rats

Document Type : Research Paper

Authors

M Meftahi
A Bahrami Samani
M.H Babaei
M Shamsaei Zafarghandi
M Ghannadi Maragheh
Abstract
153Sm-EDTMP is one of the well known radiopharmaceuticals for pain palliation of bone metastases. Despite that, it is used just in a few countries. It is due to some reasons like being costly enriched samarium that usually used as target for irradiation and short half-life of 153Sm. In this investigation, certain amounts of radiopharmaceuticals prepared by irradiation of enriched and natural samarium were injected to some normal rats. Then, the rodents were sacrificed and some of their organs were removed. All of the mentioned stages were performed in order to consider the possibility of exploiting natural samarium instead of enriched samarium by study of biodistribution of both radiopharmaceuticals in various organs especially in bone as the target tissue. At the end, the acceptable results were obtained using natural samarium in comparison with the enriched samarium from the point of view of the biodistribution studies.

Highlights

 

 

  1. Aldo N.  Serafini, “Therapy of metastatic bone pain,” J. Nucl. Med. 42 (6): 895-906 (2001).

     

  2. Nitta pandit-taskar, “Radiopharmaceutical therapy for palliation of bone pain from osseous metastases,” J. Nucl. Med. 45: 1385-1365 (2004).

     

  3. Suresh C. Srivastava, “Bone-seeking therapeutic radiopharmaceutical,” Brazilian Archives of Biology and Technology, Vol. 45, special n: 45-55 (2002).

     

  4. Albert S. Alberts, “Samarium-153-EDTMP for palliation of ankylosing spondylitis, paget’s disease and rheumatoid arthritis,” J. Nucl. Med. Vol. 36, No. 8, 1417-1420 (1995).

     

     

     

     

     

     

     

  5. Sharmila Banerjee, “177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: Novel Agents for Bone Pain Palliation and Their Comparison with 153Sm-EDTMP,” Founder’s Day Special Issue (2005).

     

  6. L. Moro, D. Fantinato, F. Frigerio, G. Shamhan, G. Angelovski, “Europium-154 contamination levels in Samarium-153-EDTMP for radionuclide therapy,” Journal of Physics: Conference Series 41, 535–537 (2006).

     

  7. G. Friedlander, J.W. Kenedy, J.M. Miller, “Nuclear and radiochemistry,” John Wiley & Sons, Inc, New York.

Keywords

Biodistribution
Radiopharmaceutical 153Sm-EDTMP
Irradiation
Natural Samarium and Enriched Samarium

  1.  

     

    1. Aldo N.  Serafini, “Therapy of metastatic bone pain,” J. Nucl. Med. 42 (6): 895-906 (2001).

       

    2. Nitta pandit-taskar, “Radiopharmaceutical therapy for palliation of bone pain from osseous metastases,” J. Nucl. Med. 45: 1385-1365 (2004).

       

    3. Suresh C. Srivastava, “Bone-seeking therapeutic radiopharmaceutical,” Brazilian Archives of Biology and Technology, Vol. 45, special n: 45-55 (2002).

       

    4. Albert S. Alberts, “Samarium-153-EDTMP for palliation of ankylosing spondylitis, paget’s disease and rheumatoid arthritis,” J. Nucl. Med. Vol. 36, No. 8, 1417-1420 (1995).

       

       

       

       

       

       

       

    5. Sharmila Banerjee, “177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: Novel Agents for Bone Pain Palliation and Their Comparison with 153Sm-EDTMP,” Founder’s Day Special Issue (2005).

       

    6. L. Moro, D. Fantinato, F. Frigerio, G. Shamhan, G. Angelovski, “Europium-154 contamination levels in Samarium-153-EDTMP for radionuclide therapy,” Journal of Physics: Conference Series 41, 535–537 (2006).

       

    7. G. Friedlander, J.W. Kenedy, J.M. Miller, “Nuclear and radiochemistry,” John Wiley & Sons, Inc, New York.

Home